TY  - JOUR
AU  - Bukkems, Vera
AU  - Necsoi, Coca
AU  - Tenorio, Carmen Hidalgo
AU  - Garcia, Coral
AU  - Rockstroh, Jürgen
AU  - Schwarze-Zander, Caroline
AU  - Lambert, John S
AU  - Burger, David
AU  - Konopnicki, Deborah
AU  - Colbers, Angela
PY  - 2020
DO  - 10.1093/cid/ciaa488
UR  - http://hdl.handle.net/10668/15427
T2  - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
AB  - This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during...
LA  - en
KW  - HIV
KW  - cobicistat
KW  - elvitegravir
KW  - pharmacokinetics
KW  - pregnancy
KW  - Anti-HIV Agents
KW  - Anti-Retroviral Agents
KW  - Female
KW  - HIV Infections
KW  - Humans
KW  - Pregnancy
KW  - Pregnancy Complications, Infectious
KW  - Pregnancy Trimester, Third
KW  - Pregnant Women
KW  - Quinolones
TI  - Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network.
TY  - research article
VL  - 71
ER  -